UNSPSC 51392803: Prinoxodan

This classification denotes a phosphodiesterase inhibitor with the molecular formula C13H14N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W4VMH2E80M, chemically known as 3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2(1h)-quinazolinone but generally known as prinoxodan, which bears US NIH Compound Identifier 5362397. European Medicines Agency schedules Prinoxodan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10048MIG.

UNSPSC 51392803 Prinoxodan, a Commodity code, covers pharmaceutical products and related health-related substances that state and local governments procure for emergency response, community health, and pharmacy benefit programs. Recent opportunities show state and local buyers purchasing naloxone (opioid antagonist) units and drug deactivation systems in bulk quantities to support public health initiatives, as well as exploring direct-to-manufacturer prescription fulfillment models to manage pharmacy costs and improve dispensing efficiency. The code sees activity from county health departments and state health and human services agencies, representing a mix of direct-purchase and early-stage strategic procurement.

Seminole County, Florida and the Texas Health and Human Services Commission represent the geographic and issuing-body spread in recent activity. Seminole County issued an IFB (Solicitation Number IFB60459723LAS, posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, supporting a fixed-fee contract model with an initial two-year term and one-year renewal option. Texas HHS issued an RFI (No. HHS0017013, posted April 3, 2026) to gather vendor capabilities around direct-to-manufacturer prescription programs for self-insured employer and government employee health plans, exploring negotiated net-pricing models independent of traditional pharmacy benefit managers, group purchasing organizations, and wholesalers. The RFI represents exploratory procurement ahead of a formal RFP. Neither solicitation specifies budget figures, set-aside restrictions, or disadvantaged-enterprise designations in available documentation.